GEOC appeared to be the VC, which was created in 2013. The company was established in Asia in China. The main office of represented VC is situated in the Shanghai.
Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Cnoga Medical, Vectorious Medical Technologies Among the most popular fund investment industries, there are Printing, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - Israel. The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The real fund results show that this VC is 3 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. The typical startup value when the investment from GEOC is 100-500 millions dollars. The high activity for fund was in 2014.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the GEOC, startups are often financed by OurCrowd, GE Healthcare, Elbit Imaging Ltd.. The meaningful sponsors for the fund in investment in the same round are York Capital Management, GE Healthcare, Elbit Imaging Ltd.. In the next rounds fund is usually obtained by OurCrowd, Go Capital, York Capital Management.
Related Funds
Funds with similar focus
Fund Name | Location |
Block.one | Cayman Islands, Midland |
China Investment Fund | China, Hong Kong, Hong Kong Island |
China Summit Capital | China, Shanghai |
Finn Evdemon Capital Partners | Central, Central Region, Singapore |
GMGMT | Bayern, Germany, Munich |
Hearst Television Inc. | New York, New York, United States |
Invia.cz | Czechia, Prague, Prague |
JSS Management | - |
Killik & Co | England, London, United Kingdom |
Mantella Venture Partners | Canada, Ontario, Toronto |
NIF SMBC Ventures | California, Palo Alto, United States |
Nissei Capital | Chiyoda, Japan |
Quaras | Japan, Tokyo |
Robeco Private Equity | - |
Shengyi Kechuang | Beijing, Beijing, China |
The Abhoca Group | - |
U.S. Department of the Treasury | District of Columbia, United States, Washington |
ValueTech Seed | Mazowieckie, Poland, Warsaw |
Weipinhui | China, Guangdong, Guangzhou |
Xiangxiang Capital | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Vectorious Medical Technologies | $9M | 09 May 2018 | Tel Aviv District | ||
Sight Diagnostics | $16M | 01 Sep 2016 | Tel Aviv-Yafo, Tel Aviv District, Israel | ||
Kaymera | $13M | 01 Jan 2015 | Israel, Tel Aviv District | ||
$463K | 31 May 2012 | Shanxi |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Vectorious Medical Technologies | $9M | 09 May 2018 | Tel Aviv District | ||
Sight Diagnostics | $16M | 01 Sep 2016 | Tel Aviv-Yafo, Tel Aviv District, Israel | ||
Kaymera | $13M | 01 Jan 2015 | Israel, Tel Aviv District | ||
$463K | 31 May 2012 | Shanxi |